Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer

被引:4
|
作者
Cascinu, S
Alessandroni, P
Rossi, D
DelFerro, E
Fedeli, A
Casadei, V
Catalano, G
机构
[1] Servizio di Oncologia Medica, Ospedale di Pesaro, 1-61100 Pesaro
关键词
colorectal cancer; 5-FU; biochemical modulation;
D O I
10.1007/s002800050499
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A total of 26 patients with advanced colorectal cancer received 60 mg/m(2) methotrexate i.v. on days 1-4; 400 mg/m(2) 5-fluorouracil i.v. on days 2, 3, 5, and 6; and 100 mg/m(2) 6S-leucovorin i.v. on days 2, 3, 5, and 6. Interferon-alpha 2b at a dose of 3 million U was given i.m. daily for the 6 days of chemotherapy. Courses were repeated every 3 weeks. There were four partial responses for a response rate of 15% (95% confidence interval 2-28%). In all, 14 patients expressed grade 3 toxicity; 9 patients had diarrhea, 3 had stomatitis, and 2 developed leukopenia. In conclusion, multimodal biochemical modulation of 5-fluorouracil, at least on this schedule, does not seem to be effective, as it results in severe toxicity.
引用
收藏
页码:385 / 386
页数:2
相关论文
共 50 条
  • [31] Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer
    Thirion, P
    Piedbois, P
    Buyse, M
    O'Dwyer, PJ
    Cunningham, D
    Man, A
    Greco, FA
    Colucci, G
    Köhne, CH
    Di Costanzo, F
    Piga, A
    Palmeri, S
    Dufour, P
    Cassano, A
    Pajkos, G
    Pensel, R
    Aykan, NF
    Marsh, J
    Seymour, T
    BRITISH JOURNAL OF CANCER, 2001, 84 (05) : 611 - 618
  • [32] Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study
    Sobrero, A
    Zaniboni, A
    Frassineti, GL
    Aschele, C
    Guglielmi, A
    Giuliani, R
    Ravaioli, A
    Lanfranco, C
    Caroti, C
    Arnoldi, E
    Barni, S
    Gallo, L
    Pessi, MA
    Turci, D
    Cortesi, E
    Grossi, F
    Frontini, L
    Piazza, E
    Bruzzi, P
    Labianca, R
    ANNALS OF ONCOLOGY, 2000, 11 (11) : 1413 - 1420
  • [33] Randornised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer
    Nogué, M
    Salud, A
    Batiste-Alentorn, E
    Saigí, E
    Losa, F
    Cirera, L
    Méndez, M
    Campos, JM
    Galan, A
    Escudero, P
    Arcusa, A
    Manzano, H
    de Mendizábal, EV
    de Olaguer, JP
    Boleda, M
    Guasch, I
    Vicente, P
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (15) : 2241 - 2249
  • [34] 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low cost chemotherapy for advanced colorectal cancer
    Sobrero, A
    Guglielmi, A
    Cirillo, M
    Recaldin, E
    Frassineti, GL
    Aschele, C
    Ravaioli, A
    Testore, P
    Caroti, C
    Gallo, L
    Pessi, MA
    Cortesi, E
    Turci, D
    Grossi, F
    Labianca, R
    BRITISH JOURNAL OF CANCER, 2001, 84 (08) : 1023 - 1028
  • [35] LACK OF EFFECTIVENESS OF COMBINED 5-FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH 5-FLUOROURACIL-RESISTANT ADVANCED COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (01): : 45 - 49
  • [36] A pilot study of adjuvant chemotherapy with double modulation of 5-Fluorouracil by Methotrexate and Leucovorin in gastric cancer patients
    De Vita, F
    Orditura, M
    Auriemma, A
    Infusino, S
    Catalano, G
    PANMINERVA MEDICA, 1999, 41 (01) : 35 - 38
  • [37] PHASE-II STUDY OF 5-FLUOROURACIL PLUS LEUCOVORIN AND INTERFERON ALPHA-2B IN ADVANCED COLORECTAL-CANCER
    SOBRERO, A
    NOBILE, MT
    GUGLIELMI, A
    MORI, A
    ASCHELE, C
    BOLLI, E
    TIXI, L
    GALLO, L
    PARODI, GC
    BRUZZI, P
    BREMA, F
    ROSSO, R
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) : 850 - 852
  • [38] A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer - A Hellenic Cooperative Oncology Group (HeCOG) study
    Kalofonos, HP
    Nicolaides, C
    Samantas, E
    Mylonakis, N
    Aravantinos, G
    Dimopoulos, MA
    Gennatas, C
    Kouvatseas, G
    Giannoulis, E
    Dervenis, C
    Basdanis, G
    Pavlidis, N
    Androulakis, I
    Fountzilas, G
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (01): : 23 - 30
  • [39] Rationale for treatment design: Biochemical modulation of 5-fluorouracil by leucovorin
    Rustum, YM
    Cao, SS
    Zhang, ZG
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1998, 4 (01): : 12 - 18
  • [40] METHOTREXATE (MTX), 5-FLUOROURACIL (FU) AND LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED HEAD AND NECK CANCER (HNC)
    OHNUMA, T
    COFFEY, V
    KOHNO, N
    BILLER, H
    HOLLAND, JF
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 209 - 209